Biodexa Pharmaceuticals Plc
BDRX · Pharmaceutical Preparations · EDGAR filings ↗
Grade
C63gen composite 42pct→63
Notable findings
- Going concern· Our requirement for additional financing in the short-term represents a material uncertainty that raises substantial doubt about our ability to continue as a going concern
- No interest coverageInterest coverage -37.75 (cannot cover interest)
- Cash burnNegative free cash flow (-7.5M)
Key metrics
Return on equity
-56.0%
Return on assets
-35.1%
ROIC
-59.6%
Debt / equity
0.0×
Interest coverage
-37.8×
Current ratio
2.0×
Free cash flow
-$8M
Tangible book value
$15M
Cash & investments
$11M
Cash runway
6q
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Chief Executive Officer | Officer | — |
| Ann Merchant | Director | — |
| Sijmen de Vries | Director | — |
| Simon Turton | Director | — |
| Stephen Parker | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04315064 ↗ | Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma Medulloblastoma | EARLY_PHASE1 | Completed | 2023-05-02 |
| NCT04264143 ↗ | CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas | PHASE1 | Completed | 2022-04-25 |
| NCT03566199 ↗ | MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma Diffuse Intrinsic Pontine Glioma | PHASE1/PHASE2 | Completed | 2021-03-31 |
| NCT03490396 ↗ | Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients Oral Mucositis | PHASE4 | Terminated | 2019-11-15 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-27 | 2025-12-31 | 0001214659-26-003921 ↗ |
| 20-F | 2025-04-11 | 2024-12-31 | 0001214659-25-005742 ↗ |
| 20-F | 2024-04-19 | 2023-12-31 | 0001214659-24-007125 ↗ |
| 20-F | 2023-04-28 | 2022-12-31 | 0001214659-23-006169 ↗ |
| 20-F | 2022-04-26 | 2021-12-31 | 0001214659-22-005798 ↗ |
| 20-F | 2021-04-30 | 2020-12-31 | 0001214659-21-004730 ↗ |
| 20-F | 2020-06-15 | 2019-12-31 | 0001214659-20-005615 ↗ |
| 20-F | 2019-04-30 | 2018-12-31 | 0001214659-19-003052 ↗ |
| 20-F | 2018-04-24 | 2017-12-31 | 0001214659-18-002960 ↗ |
| 20-F | 2017-04-06 | 2016-12-31 | 0001214659-17-002415 ↗ |
| 20-F | 2016-04-14 | 2015-12-31 | 0001214659-16-010859 ↗ |